{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:29:35Z","timestamp":1787164175861,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>High levels of plasma homocysteine occur almost uniformly in patients with end-stage renal disease (ESRD). IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis and a common cause of ESRD in young adults. Here, we aimed to detect whether homocysteine was elevated and associated with clinical-pathologic manifestations of IgAN patients and tested its causal effects using a two-sample Mendelian randomization (MR) approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>For observational analysis, 108 IgAN patients, 30 lupus nephritis (LN) patients, 50 minimal change disease (MCD) patients, and 206 healthy controls were recruited from April 2014 to April 2015. Their plasma homocysteine was measured and clinical-pathologic manifestations were collected from medical records. For MR analysis, we further included 1686 IgAN patients. The missense variant methylenetetrahydrofolate reductase C677T (rs1801133) was selected as an instrument, which was genotyped by TaqMan allele discrimination assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Majority of IgAN patients (93.52%, 101\/108) showed elevated levels of plasma homocysteine (&gt;10 \u03bcmol\/L). Plasma homocysteine in IgAN patients was significantly higher than that in MCD patients (median: 18.32\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      11.15 \u03bcmol\/L,\n                      <jats:italic toggle=\"yes\">Z<\/jats:italic>\n                      \u200a=\u200a\u22125.29,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a0.01) and in healthy controls (median: 18.32\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      10.00 \u03bcmol\/L,\n                      <jats:italic toggle=\"yes\">Z<\/jats:italic>\n                      \u200a=\u200a\u22128.76,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a0.01), but comparable with those in LN patients (median: 18.32 L\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      14.50 \u03bcmol\/L,\n                      <jats:italic toggle=\"yes\">Z<\/jats:italic>\n                      \u200a=\u200a\u22121.32,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a0.19). Significant differences were observed in sub-groups of IgAN patients according to quartiles of plasma homocysteine for male ratio (22.22%\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      51.85%\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      70.37%\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      70.37%,\n                      <jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u200a=\u200a14.29,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a0.01), serum creatinine (median: 77.00\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      100.00\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      129.00\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      150.00 \u03bcmol\/L,\n                      <jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u200a=\u200a34.06,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a0.01), estimated glomerular filtration rate (median: 100.52\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      74.23\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      52.68\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      42.67 mL\u00b7min\n                      <jats:sup>\u22121<\/jats:sup>\n                      \u00b71.73 m\n                      <jats:sup>\u22122<\/jats:sup>\n                      ,\n                      <jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u200a=\u200a21.75,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a0.01), systolic blood pressure (median: 120.00\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      120.00\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      125.00\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      130.00 mmHg,\n                      <jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u200a=\u200a2.97,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a0.05), diastolic blood pressure (median 80.00\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      75.00\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      80.00\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      81.00 mmHg,\n                      <jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u200a=\u200a11.47,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a0.01), and pathologic tubular atrophy and interstitial fibrosis (T) (T0\/T1\/T2: 62.96%\/33.33%\/3.70%\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      29.63%\/40.74%\/29.63%\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      24.00%\/48.00%\/28.00%\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      14.81%\/37.04%\/48.15%,\n                      <jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u200a=\u200a17.66,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a0.01). The coefficient of each rs1801133-T allele on homocysteine levels after controlling age and sex was 7.12 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a0.01). MR estimates showed causal positive effects of homocysteine on serum creatine (\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      \u200a=\u200a0.76,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a0.02), systolic blood pressure (\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      \u200a=\u200a0.26,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a0.02), diastolic blood pressure (\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      \u200a=\u200a0.20,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a0.01), and pathologic T lesion (\n                      <jats:italic toggle=\"yes\">\u03b2<\/jats:italic>\n                      \u200a=\u200a0.01,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a0.01) in IgAN.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>By observational and MR analyses, consistent results were observed for associations of plasma homocysteine with serum creatinine, blood pressures, and pathologic T lesion in IgAN patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000000613","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T05:47:28Z","timestamp":1578894448000},"page":"277-284","source":"Crossref","is-referenced-by-count":17,"title":["Homocysteine and IgA nephropathy: observational and Mendelian randomization analyses"],"prefix":"10.1097","volume":"133","author":[{"given":"Yue-Miao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Fang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Cheng","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"key":"R1-20230813","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/sj.ki.5000292","article-title":"Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA?","volume":"69","author":"Nair","year":"2006","journal-title":"Kidney Int"},{"key":"R2-20230813","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40620-019-00618-x","article-title":"The relationship between the concentration of plasma homocysteine and chronic kidney disease: a cross sectional study of a large cohort","volume":"32","author":"Cohen","year":"2019","journal-title":"J Nephrol"},{"key":"R3-20230813","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1681\/ASN.V104891","article-title":"Hyperhomocysteinemia in chronic renal disease","volume":"10","author":"Bostom","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"R4-20230813","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/jamainternmed.2016.4687","article-title":"Efficacy of folic acid therapy on the progression of chronic kidney disease: the renal substudy of the china stroke primary prevention trial","volume":"176","author":"Xu","year":"2016","journal-title":"JAMA Intern Med"},{"key":"R5-20230813","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.3760\/cma.j.issn.0366-6999.20140391","article-title":"Potential association of hyperhomocysteinemia with the progression of IgA nephropathy: a retrospective study","volume":"127","author":"Duan","year":"2014","journal-title":"Chin Med J"},{"key":"R6-20230813","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1161\/01.CIR.94.11.2743","article-title":"Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations","volume":"94","author":"Robinson","year":"1996","journal-title":"Circulation"},{"key":"R7-20230813","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1046\/j.1523-1755.1998.00918.x","article-title":"Major determinants of hyperhomocysteinemia in peritoneal dialysis patients","volume":"53","author":"Vychytil","year":"1998","journal-title":"Kidney Int"},{"key":"R8-20230813","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1001\/jama.1993.03510220049033","article-title":"Vitamin status and intake as primary determinants of homocysteinemia in an elderly population","volume":"270","author":"Selhub","year":"1993","journal-title":"JAMA"},{"key":"R9-20230813","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/ajcn\/82.4.806","article-title":"Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials","volume":"82","year":"2005","journal-title":"Am J Clin Nutr"},{"key":"R10-20230813","doi-asserted-by":"crossref","first-page":"k601","DOI":"10.1136\/bmj.k601","article-title":"Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians","volume":"362","author":"Davies","year":"2018","journal-title":"BMJ"},{"key":"R11-20230813","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1046\/j.1523-1755.63.s84.52.x","article-title":"Genetic determinants of the homocysteine level","volume":"63","author":"Sunder-Plassmann","year":"2003","journal-title":"Kidney Int Suppl"},{"key":"R12-20230813","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/oxfordjournals.aje.a010290","article-title":"5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review","volume":"151","author":"Botto","year":"2000","journal-title":"Am J Epidemiol"},{"key":"R13-20230813","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/gepi.21758","article-title":"Mendelian randomization analysis with multiple genetic variants using summarized data","volume":"37","author":"Burgess","year":"2013","journal-title":"Genet Epidemiol"},{"key":"R14-20230813","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/sim.6522","article-title":"Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome","volume":"34","author":"Greco","year":"2015","journal-title":"Stat Med"},{"key":"R15-20230813","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1172\/JCI10588","article-title":"Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model","volume":"107","author":"Hofmann","year":"2001","journal-title":"J Clin Invest"},{"key":"R16-20230813","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1161\/01.ATV.0000013288.35930.90","article-title":"Folic acid treatment reduces chemokine release from peripheral blood mononuclear cell in hyperhomocysteinemic subjects","volume":"22","author":"Holven","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R17-20230813","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1023\/A:1011088431191","article-title":"Homocysteine augments cytokine-induced chemokine expression in human vascular smooth muscle cells: implications for atherogenesis","volume":"25","author":"Desai","year":"2001","journal-title":"Inflammation"},{"key":"R18-20230813","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1042\/BJ20051810","article-title":"Homocysteine stimulates the expression of monocyte chemoattractant protein-1 receptor (CCR2) in human monocytes: possible involvement of oxygen free radical","volume":"398","author":"Siow","year":"2006","journal-title":"Biochem J"},{"key":"R19-20230813","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.nut.2005.01.011","article-title":"Homocysteine at pathophysiological concentrations activates human monocyte and induces cytokine expression and inhibits macrophage migration inhibitory factor expression","volume":"21","author":"Su","year":"2005","journal-title":"Nutrition"},{"key":"R20-20230813","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/00335510500429821","article-title":"Increased levels of C-reactive proteins and interleukin-6 in hyperhomocysteinemic subjects","volume":"66","author":"Holven","year":"2006","journal-title":"Scand J Clin Lab Invest"},{"key":"R21-20230813","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/ajcn\/82.2.335","article-title":"A pro-inflammatory state is associated with hyperhomocysteinemia in the elderly","volume":"82","author":"Gori","year":"2005","journal-title":"Am J Clin Nutr"},{"key":"R22-20230813","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/rheumatology\/kel082","article-title":"Relationship of plasma interleukin-18 concentrations to traditional and nontraditional cardiovascular factors in patients with systemic lupus erythematosus","volume":"45","author":"Tso","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R23-20230813","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.clinbiochem.2004.01.003","article-title":"Endothelial cell adhesion molecules in healthy adults during acute hyperhomocysteinemia and mild hypertriglyceridemia","volume":"37","author":"Mansoor","year":"2004","journal-title":"Clin Biochem"},{"key":"R24-20230813","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1046\/j.1365-2362.2003.01189.x","article-title":"Expression of matrix metalloproteinases-9 in mononuclear cells of hyperhomocystaeinemic subjects","volume":"33","author":"Holven","year":"2003","journal-title":"Eur J Clin Invest"},{"key":"R25-20230813","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/eurheartj\/ehn515","article-title":"Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials","volume":"30","author":"Antoniades","year":"2009","journal-title":"Eur Heart J"},{"key":"R26-20230813","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1017\/S0007114518002477","article-title":"Effect of long-term low-dose folic acid supplementation on degree of total homocysteine-lowering: major effect modifiers","volume":"120","author":"Wang","year":"2018","journal-title":"Br J Nutr"},{"key":"R27-20230813","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ije\/dyg070","article-title":"\u2018Mendelian randomization\u2019: can genetic epidemiology contribute to understanding environmental determinants of disease?","volume":"32","author":"Smith","year":"2003","journal-title":"Int J Epidemiol"},{"key":"R28-20230813","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jama.2015.2274","article-title":"Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial","volume":"313","author":"Huo","year":"2015","journal-title":"JAMA"},{"key":"R29-20230813","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2147\/DMSO.S205379","article-title":"Plausible relationship between homocysteine and obesity risk via MTHFR gene: a meta-analysis of 38,317 individuals implementing Mendelian randomization","volume":"12","author":"Fu","year":"2019","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R30-20230813","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3945\/ajcn.115.116038","article-title":"Is there a causal role for homocysteine concentration in blood pressure? A Mendelian randomization study","volume":"103","author":"Borges","year":"2016","journal-title":"Am J Clin Nutr"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000000613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T21:25:48Z","timestamp":1722288348000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000000613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,7]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000000613","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,7]]}}}